Entries |
Document | Title | Date |
20080206336 | Novel Composition Comprising Rosiglitazone and Another Antidiabetic Agent - An oral dosage form comprising an erodable core, which core comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, the core having a coating with one or more openings, characterised in that the coating is erodable under predetermined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine. | 08-28-2008 |
20080213364 | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation - The present invention provides pharmaceutical compositions for oral administration comprising pyridoxal-5′-phosphate wherein the compositions contain an amount of pyridoxal-5-phosphate of at least 50% w/w and methods of preparing the pharmaceutical compositions. The present invention also provides a pre-blend for the manufacture of a pyridoxal 5′-phosphate oral dosage form comprising pyridoxal 5′-phosphate and microcrystalline cellulose, wherein the pre-blend contains an amount pyridoxal-5-phosphate greater than or equal to 80% w/w. | 09-04-2008 |
20080213365 | UNUSUALLY STABLE GLASSES AND METHODS FOR FORMING SAME - The present invention provides vapor deposition-methods that overcome the kinetic restrictions imposed by more conventional vapor deposition processes and liquid-cooling techniques to form amorphous molecular solids with greatly enhanced-stabilities. The present methods produce amorphous molecular solids having stabilities, as measured by fictive temperature, that cannot be achieved using liquid-cooling methods. | 09-04-2008 |
20080226717 | Sublingual Coated Tablet - The present invention relates to a sublingual coated tablet and to a method for the preparation thereof. The tablet includes a core devoid of a pharmaceutically active substance, and a coating including at least one active substance. The preferred active substance is an opioid analgesic. | 09-18-2008 |
20080226718 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases - The use is described of compounds of formula (I) wherein A is chosen from a phenyl or a heterocyclic ring with 5 or 6 members containing up to two heteroatoms chosen from nitrogen, oxygen and sulfur, X and Y represent carbon or nitrogen, and R1-R6 are as described in the specification, in the prevention and/or treatment of inflammatory and autoimmune diseases. | 09-18-2008 |
20080248115 | Combinations of statins and anti-obesity agent - Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components. | 10-09-2008 |
20080260826 | Pharmaceutical composition and process - The present invention relates to a method of forming granules of (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate; hydrochloride salt (I), comprising mixing I, with a granulating amount of a granulating liquid, and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer as a binder and solubility enhancer to form wet granules which are then dried to remove the granulating liquid. | 10-23-2008 |
20080260827 | RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE - A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three consecutive days per month is useful for treating or preventing osteoporosis and other bone metabolic disorders. | 10-23-2008 |
20080268048 | PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND FOR REDUCING THE RISK OF CONGENITAL ABNORMALITIES - The pharmaceutical composition for oral contraception and for reducing the risk of congenital abnormalities contains, in a daily dosage unit, 2.0 mg or 1.5 mg of 17α-cyanomethyl-17β-hydroxyoestra-4,9-dien-3-one (dienogest), 0.015 mg of 17α-ethynyloestradiol (ethynyloestradiol), and (6S)-5-methyl-tetrahydrofolate, preferably as the calcium salt of (6S)-5-methyltetrahydrofolic acid (metafolin), together with one or more pharmaceutically acceptable auxiliaries/carriers. A kit for oral contraception contains 21 daily dosage units of the pharmaceutical composition and 7 daily dosage units solely containing (6S)-5-methyltetrahydrofolate, preferably in the form of metafolin. | 10-30-2008 |
20080268049 | Stable Solid Dosage Forms of Amlodipine and Benazepril - The technical field of the invention relates to stable solid dosage forms of amlodipine besylate and benazepril hydrochloride; and processes for their preparation. In particular, the solid dosage forms having reduced levels of 3-ethyl methyl [(2-aminoethoxy)methyl](2-chlorophenyl)methylpyridine-3,5 dicarboxylate (“impurity D”) and total impurities when free of dicalcium phosphate. | 10-30-2008 |
20080286359 | Low Dosage Forms Of Risedronate Or Its Salts - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 11-20-2008 |
20080299198 | Polystyrene sulfonate polymer tablets, their preparation and use - The present invention provides tablets containing at least about 70% of polystyrene sulfonate polymer, binder and moisture. The invention further relates to methods of treating medical conditions including antibiotic-associated diarrhea such as that caused by | 12-04-2008 |
20080311202 | Pharmaceutical Composition Containing Donepezil Hydrochloride, Tablets Produced Therefrom and Methods for Producing the Same - A pharmaceutical composition is provided according to the invention which is suited for the production of tablets by direct compression and which contains donepezil hydrochloride of polymorphic form I. The polymorphic form I of donepezil hydrochloride in the directly compressed tablet is also stable during long storage. | 12-18-2008 |
20080311203 | Oral Formulation of Anhydrous Olanzapine Form I - The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i). | 12-18-2008 |
20080317856 | Compositions Containing A Capillary -Active System With Application -Relevant Differentiability, And The Use Thereof - This invention relates to compositions with a capillary-active system with application-relevant differentiability and synergistic potential for use in mammals, especially humans. | 12-25-2008 |
20080317857 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock - The use of vacuolar ATPase inhibitors in the prevention and/or treatment of septic shock is herein described. Vacuolar ATPase inhibitors are selected among products of natural, semi-synthetic or synthetic origin. | 12-25-2008 |
20090011020 | Gastroresistant Pharmaceutical Formulations Containing Rifaximin - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 01-08-2009 |
20090022799 | COMPOSITIONS THAT CONTAIN BETA-GLUCAN TO BE USED FOR THE PREVENTION AND TREATMENT OF DISEASE AND METHODS FOR THEIR USE - This application for patent discloses β-Glucan containing compositions, dosage forms, delivery methods, and techniques for the purposes of preventing and treating mucositis through wound healing and tissue re-organization, as well as the treatment of immune disorders such as Alzheimer's disease, Multiple Sclerosis and Parkinson's disease. β-Glucan containing compositions, dosage forms and methods to deliver therapeutic and prophylactic vaccines and anti-cancer drugs are also disclosed, as are methods to stabilize a drug to enhance its shelf life and to enhance the level and duration of its bioactivity. | 01-22-2009 |
20090022800 | Coating for small bodies - Coated bodies and a process, apparatus and article of manufacture for coating bodies in a non-fluidized state, including tablets, by producing an upward spray of coating fluid by means of a two-fluid nozzle as defined herein and contacting said bodies with said spray of coating fluid in a non-fludized state; wherein, before contacting the bodies with said spray, providing the bodies with a spinning movement by acentral impact of gas jets directed upward to intersect the centerline of said spray; guiding the spinning bodies by said gas jets towards a central position over the two-fluid nozzle, thereby increasing the number of suspended bodies contacting the spray; providing atomization gas to the two-fluid nozzle in an amount less than the one which after moderation by means of muffling gas would scatter the bodies in the spray zone; and pneumatically muffling the atomization gas just above the nozzle to reduce the spray body scattering effect thereof. | 01-22-2009 |
20090028943 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt and a plastic filler with a high surface area, excluding lactose. | 01-29-2009 |
20090068265 | ECKLONIA CAVA EXTRACTS FOR ALLEVIATING OR PREVENTING ASTHMATIC REACTIONS - A method of alleviating or preventing inflammation in an animal is provided. In concrete, the method comprises the step of administering to an animal a composition including an Ecklonia cava extract in an amount effective to suppress SOCS-3 expression in the animal to thereby alleviate or prevent inflammation in the animal. | 03-12-2009 |
20090068266 | SIROLIMUS HAVING SPECIFIC PARTICLE SIZE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Sirolimus particles having d | 03-12-2009 |
20090068267 | Novel Pharmaceutical Compositions - The present invention relates to novel lamivudine/cyclodextrin complexes and processes for preparing said complexes. The present invention also relates to novel solid pharmaceutical compositions comprising lamivudine, wherein lamivudine is present in the form of said lamivudine/cyclodextrin complexes. The present invention further relates to processes for preparing said compositions. | 03-12-2009 |
20090074864 | NOVEL ANTIMICROBIAL PEPTIDES WITH HEPARIN BINDING ACTIVITY - The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition. | 03-19-2009 |
20090074865 | Oral formulations of glycyl-2-methylprolyl-glutamate - Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy. | 03-19-2009 |
20090087489 | IMATINIB COMPOSITIONS - The invention relates to a pharmaceutical composition, preferably a tablet, containing about 23-29% w/w imatinib and processes for its preparation. | 04-02-2009 |
20090092670 | LONG ACTING DUAL RELEASE PRODUCT CONTAINING CARBINOXAMINE AND PSEUDOEPHEDRINE - Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants. | 04-09-2009 |
20090104265 | Polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl) 2-[2-methyl-4,5-(methylenedioxy)phenylacetyl] thiophene-3-sulfonamide, sodium salt - N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyl-acetyl]thiophene-3-sulfonamide, sodium salt, is provided herein in the form of three polymorphs (Forms A, B and C). Forms A, B and C are specified by the peaks in their X-ray powder diffraction patterns, their absorption peaks in their infrared absorption spectra, their peaks in their Raman spectra and their melting points. | 04-23-2009 |
20090110729 | SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM - This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. | 04-30-2009 |
20090117185 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa - The invention relates to 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events. | 05-07-2009 |
20090130209 | Novel Pyridazinone Derivatives - Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R | 05-21-2009 |
20090148526 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 06-11-2009 |
20090162435 | MANUFACTURE OF TABLET - The present invention features a method of manufacturing a tablet containing a pharmaceutically active agent by the steps of: (a) adding a powder containing a pharmaceutically-acceptable carrier to a die cavity; (b) injecting a liquid drug composition containing the pharmaceutically active agent into the die cavity such that the liquid drug composition contacts the powder; (c) compressing the combination of the powder and the liquid drug composition within the die cavity to form the tablet; and (d) removing the tablet from the die cavity. | 06-25-2009 |
20090169623 | Use of ginsenosides and extracts containing them - The present invention relates to the use of ginsenosides and a plant extract containing ginsenosides in a cosmetic or pharmaceutical composition or in a food supplement for the protection of the skin against deleterious effects of stress or irradiation e.g. sunlight or UV irradiation. | 07-02-2009 |
20090181085 | UTILIZATION OF DIALKYLFUMARATES - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | 07-16-2009 |
20090186083 | METHOD FOR STABILIZATION OF ISOXAZOLE COMPOUND | 07-23-2009 |
20090186084 | FORM OF ADMINISTRATION OF RACECADOTRIL - The present invention relates to a new racecadotril formulation in the form of tablets, the preparation process thereof and the use thereof to treat diarrhoea. | 07-23-2009 |
20090186085 | Methods and Apparatus For Determining Formulation Orientation of Multi-Layered Pharmaceutical Dosage Forms - Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet. | 07-23-2009 |
20090208573 | NOVEL POLYMORPH FORM OF IRBESARTAN - New form of irbesartan having favourable chargeability is prepared from the alcoholic/etheric or ketonic solution of irbesartan after slow cooling with sporadic or light agitation and alternatively new crystalline form of an acid addition salt of irbesartan is prepared from the aqueous solution of a sodium salt of irbesartan after strongly acidifying aforesaid solution and subsequently adjusting pH with an alkali. Those are used in manufacturing a pharmaceutical composition. | 08-20-2009 |
20090208574 | DIP COATED COMPOSITIONS CONTAINING A STARCH HAVING A HIGH AMYLOSE CONTENT - The present invention features a method of making a coated tablet by dipping a core comprising an active agent into a coating liquid and drying said dipped core to form a outer-coating on the core, wherein the coating liquid contains at least one a starch having an amylose content of at least about 50 percent by weight of said starch. | 08-20-2009 |
20090214645 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT DRUG, A PH MODIFIER AND A RETARDING AGENT - The present invention concerns pharmaceutical compositions comprising a pH-dependent drug compound and a pH modifier. | 08-27-2009 |
20090214646 | PHARMACEUTICAL FORMULATIONS CONTAINING CLOPIDOGREL - The present invention relates to a composition comprising a pharmaceutically acceptable salt of Clopidogel and isomalt as a diluent, to the use of said composition in the elaboration of an oral pharmaceutical formulation, as well as to an oral pharmaceutical formulation comprising said composition. | 08-27-2009 |
20090220596 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix - A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms. | 09-03-2009 |
20090220597 | RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose. | 09-03-2009 |
20090252792 | METHOD TO REDUCE THE SYMPTOMS OF HEARTBURN AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) BY SPECIFIC POLYSACCHARIDES - The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms or heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low pH. Such a preparation is particularly effective in reducing the symptoms of heartburn and/or gastro-oesophageal reflux disease, particularly when consumed in dry form. | 10-08-2009 |
20090252793 | PHARMACEUTICAL COMPOSITIONS - Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect. | 10-08-2009 |
20090280177 | Pharmaceutical preparation for treating fibromyalgia - It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent salazosulfapyridine was administered to fibromyalgia patients. Unexpectedly, salazosulfapyridine was seen to be effective in fibromyalgia patients in whom neither the rheumatoid factor nor an immune disorder was detectable, in particular to relieve pain of enthesitis. Furthermore, salazosulfapyridine was also effective to alleviate enthesitis and to relieve pain in fibromyalgia. In addition, the combined use of salazosulfapyridine with a corticosteroid or a nonsteroidal anti-inflammatory agent potentiated the therapeutic effect of salazosulfapyridine in clinical patients to whom salazosulfapyridine alone was not effective enough. | 11-12-2009 |
20090280178 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof - Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation. | 11-12-2009 |
20090285888 | DERIVATIVES OF DIHYDROXYPHENYLALANINE - The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease. | 11-19-2009 |
20090285889 | MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME - The invention relates to a modified release (e.g., extended release) tablet composition for oral administration comprising: (a) a dihydropyridine compound or a prodrug or salt thereof; (b) a first release control agent; (c) a second release control agent; and (d) a third release control agent; wherein said second release control agent has a higher viscosity than said first release control agent. The invention also relates to methods for making such modified release (e.g., extended release) tablet compositions. After tableting, such compositions exhibit a release profile that is approximately zero order without the need of a coating. | 11-19-2009 |
20090297601 | Dosage form time-lagged of drugs for the therapy of insomnia - The invention is concerned with methods and compositions for treating insomnia, and provides a dosage form containing a drug substance useful in the treatment of insomnia, the dosage form being adapted to release said drug substance after a lag time during which substantially no drug substance is released, the lag time being about at least one hour after administration of the dosage form. | 12-03-2009 |
20090304795 | TABLETS WITH IMPROVED DRUG SUBSTANCE DISPERSIBILITY - The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises
| 12-10-2009 |
20090311322 | ATORVASTATIN FORMULATION - Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention. | 12-17-2009 |
20090317466 | Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine - Pharmaceutical composition, containing fixed doses of hydroxyurea and didanosine, a method of manufacturing such composition, and to the use of the composition for the treatment of retroviral infections. | 12-24-2009 |
20090324718 | IMATINIB COMPOSITIONS - Provided are compositions of imatinib, methods for their preparation, and methods for treatment using the same. | 12-31-2009 |
20100003321 | SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME - Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made. | 01-07-2010 |
20100003322 | ENTERIC COATED HYDROPHOBIC MATRIX FORMULATION - An enteric coated hydrophobic matrix tablet for soluble, freely soluble and very soluble drugs. | 01-07-2010 |
20100008988 | TABLET COMPOSITIONS OF AMINE POLYMERS - The present invention provides pharmaceutical compositions, essentially comprising less than about 95% by weight of an aliphatic amine polymer. The present invention relates to pharmaceutical compositions comprising aliphatic amine polymers of sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride; and methods of preparing pharmaceutical compositions thereof. | 01-14-2010 |
20100015225 | SOLID DISPERSION OF A NEUROKININ ANTAGONIST - Solid dispersion comprising (4R)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N—[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically acceptable salt or solvate thereof and a carrier. Pharmaceutical compositions comprising such solid dispersion are useful to treat patients who have functional motility disorders of the viscera, especially irritable bowel syndrome or functional dyspepsia, or urinary bladder disorders, especially urinary incontinence. | 01-21-2010 |
20100028428 | FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-- BETA-PHENYL-3-QUINOLINEETHANOL - The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1 -naphthalenyl-beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation. | 02-04-2010 |
20100028429 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 02-04-2010 |
20100034877 | USE OF LACTOBACILLUS FOR TREATMENT OF VIRUS INFECTIONS - The present technology relates to the use of at least one strain of probiotic bacteria selected from | 02-11-2010 |
20100034878 | COMBINATION OF VITAMIN K AND VITAMIN K ANTAGONIST SUCH AS R-ISOMER OF WARFARIN, PHENPROCOUMON OR R-ISOMER OF PHENPROCOUMON AS ANTICOAGULANT THERAPY - Medications which are derived by combining one or more doses of the agonist, vitamin K, with doses of one or more selected vitamin K antagonists such as the R-isomer of warfarin, the R-isomer of phenprocoumon, or the racemic phenprocoumon are useful in anticoagulant therapy. These products are designed to minimize or circumvent the detrimental impact of newly identified genetic-based variables that currently significantly complicate the therapeutic response of individual patients to anticoagulation therapy. | 02-11-2010 |
20100040682 | FENOFIBRATE TABLETS - The present invention relates to a novel galenic formulation of fenofibrate for oral administration and to the process for its preparation. | 02-18-2010 |
20100040683 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-18-2010 |
20100040684 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-18-2010 |
20100047346 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-25-2010 |
20100047347 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-25-2010 |
20100047348 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-25-2010 |
20100062063 | LIGHT-STABLE SOLID PHARMACEUTICAL COMPOSITION OF RAMOSETRON - Provided is a preparation of ramosetron which is stable under irradiation with light. The solid pharmaceutical composition of the present invention can provide a stable preparation by blending a compound absorbing light having a specific wavelength with ramosetron which is unstable, usually under irradiation with light, or a pharmaceutically acceptable salt thereof. Particularly, this technique is useful because it is adaptable to a preparation containing ramosetron or a pharmaceutically acceptable salt thereof at a low content or an orally disintegrating tablet containing ramosetron or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by blending a compound having characteristics of absorbing light having a specific wavelength. | 03-11-2010 |
20100068271 | Divisible Osmotic Dosage Forms and Methods of Use - Described are specialized pharmaceutical dosage forms, e.g., osmotic delivery systems produced to be divisible into two useable half-strength tablets. | 03-18-2010 |
20100068272 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS - The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups. | 03-18-2010 |
20100068273 | PHARMACEUTICAL FORMULATION, ITS USE, AND METHOD FOR ITS MANUFACTURE - A pharmaceutical formulation of a calcium salt and a dry plant extract in the form of a coated tablet, in which the formulation has a core of at least one dry plant extract, enveloped by at least one coating of at least one calcium salt. The plant extracts for the core may be selected from: | 03-18-2010 |
20100086593 | DOSAGE FORMS OF BISPHOSPHONATES - Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 04-08-2010 |
20100098759 | CONTROLLED-RELEASE PREPARATION CONTAINING CILOSTAZOL AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formulation. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a constant cilostazol level in the blood through a slow release while it resides in the stomach and intestines over a long period of time, thereby increasing the absorption of cilostazol in the small intestine, the major absorption site of cilostazol, as well as minimizing adverse effects caused by rapid release and making it easy for a patient to take the drug. | 04-22-2010 |
20100104640 | PHARMACEUTICAL COMPOSITIONS COMPRISING IRBESARTAN - The present invention relates to a pharmaceutical composition comprising irbesartan. | 04-29-2010 |
20100143473 | COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS - A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions. | 06-10-2010 |
20100143474 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The embodiments relate to derivatives of 9-alkyl-β-carboline, their production and pharmaceutical compositions containing these 9-alkyl-β-carboline derivatives. Further, the use of 9-alkyl-β-carboline derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer's disease and Parkinson's disease is described. Additionally, these effects can be utilized for the cultivation of cells such as dopaminergic cells or stem cells which shall be engrafted for the treatment of Parkinson's disease. | 06-10-2010 |
20100159005 | COMBINATION OF TRIAZINE DERIVATIVES AND PPARalpha AGONISTS - The present patent application relates to combinations of triazine derivatives and of PPARα agonists. | 06-24-2010 |
20100159006 | IMPROVED ANTIMICROBIAL PEPTIDES - The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity | 06-24-2010 |
20100166859 | NOVEL NUTRACEUTICAL COMPOSITIONS AND USE THEREOF - The invention relates to a novel nutraceutical composition containing at least one tripeptide as active ingredient. The term “nutraceutical' as used herein denotes a usefulness in both the nutritional and pharmaceutical field of application. Thus, the novel nutraceutical compositions can find use as supplement to food and beverages, and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations such as capsules or tablets, or liquid formulations, such as solutions or suspensions. As will he evident from the foregoing, the term nutraceutical composition also comprises food and beverages containing the above-specified active ingredients, for example protein hydrolysates which are rich in tripeptides according to the invention. The compositions are useful to improve cognitive functions such as learning, memory and alertness and for the treatment of a disorder connected to impaired neurotransmission and of conditions resulting from hypoxia and for alleviating neuropathic pain. | 07-01-2010 |
20100166860 | Medicine for treating gastrointestinal disorder including acquired lactose-intolerance irritable bowel syndrome - A method and a medicine for treating a human having a gastrointestinal disorder that includes acquired lactose-intolerance irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the human. The medicine includes ducosate sodium, tolterodine salt and imipramine salt. | 07-01-2010 |
20100172986 | CONTROLLED RELEASE COMPOSITION AND PREPARATION THEREOF - The present invention relates to a controlled release composition comprising hydrophobic cellulose, methacrylic acid copolymer and active ingredient in a form of uniform state. The present invention also relates to a method of preparing a controlled release tablet. | 07-08-2010 |
20100178342 | Solid Pharmaceutical Preparation - The invention relates to a solid pharmaceutical preparation containing one or more solid carriers and/or excipients and an active substance selected from among the Monoamine Neurotransmitter Re-uptake Inhibitors which have a 2,3-disubstituted tropane structure, the preparation thereof and use thereof for preparing a pharmaceutical composition for the treatment or prevention of central-nervous diseases or disorders. | 07-15-2010 |
20100189786 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A crystalline salt of 2-[(1R)-3-[bis(1-methylethyl)amino]- | 07-29-2010 |
20100189787 | Delayed release rasagiline citrate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
20100189788 | Delayed release rasagiline base formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
20100189789 | Micronized Tanaproget, Compositions, and Methods of Preparing the Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 07-29-2010 |
20100196475 | CONTROLLED RELEASE TABLET FORMULATION CONTAINING MAGNESIUM ALUMINOMETASILICATE - The present invention relates to a controlled pharmaceutical dosage forms for oral administration, and in particular to the excipients used to prepare such medicaments. For example, a dosage form for oral administration is provided consisting of a minimum of 15% w/w of magnesium aluminometasilicate, one or more pharmaceutically active agents and optionally one or more pharmaceutically acceptable diluents. | 08-05-2010 |
20100196476 | PROCESS FOR THE PREPARATION AND PHARMACEUTICAL FORMULATIONS FOR 4-QUINOLINONES AND QUINOLINES AND USE THEREOF - The present invention describes novel 4-quinolinones corresponding to formula (I) and quinoline derivatives thereof as formula (II), process of preparation thereof, pharmaceutical formulations comprising said 4-quinolinones and pharmaceutical application thereof for diseases related to disorders of white blood cells, such as inflammatory and autoimmune diseases, including rheumatism, as well as the use as anti-coagulant, antivenin, analgesic and for antithrombotic purposes. | 08-05-2010 |
20100203128 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 08-12-2010 |
20100203129 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY - The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual. | 08-12-2010 |
20100203131 | ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE - An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 08-12-2010 |
20100203132 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and AT1 Receptor Antagonists - A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT | 08-12-2010 |
20100203133 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 08-12-2010 |
20100209505 | Controlled release pharmaceutical formulations of nitazoxanide - Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided. | 08-19-2010 |
20100209506 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. | 08-19-2010 |
20100209507 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 08-19-2010 |
20100221336 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND A PROTON PUMP INHIBITOR - Embodiments of the present invention provide methods of treating pain, arthritis and inflammation comprising administering naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor. Further embodiments provide pharmaceutical compositions comprising naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor. | 09-02-2010 |
20100221337 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND AN H2 RECEPTOR ANTAGONIST - Embodiments of the present invention provide methods of treating pain, arthritis and inflammation comprising administering naproxen 2(methanesulfonyl)ethyl ester and an H2 receptor antagonist. Further embodiments provide pharmaceutical compositions comprising naproxen 2(methanesulfonyl)ethyl ester and an H2 receptor antagonist. | 09-02-2010 |
20100239669 | Combinations of statins and anti-obesity agent - Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components. | 09-23-2010 |
20100247648 | ANTIMICROBIAL COMPOUNDS - The invention relates to compositions comprising a compound based on the general formula (I) | 09-30-2010 |
20100272802 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES - The present invention relates to the use of a pharmaceutical composition comprising at least one strontium salts for the preparation of a medicament for treatment and prevention of gingivitis, periodontitis (aggressive and chronic), periodontitis as a 5 manifestation of systemic diseases and/or necrotizing periodontal diseases. The composition preferably comprises strontium carbonate, strontium chlorides and/or strontium renalate. Further included may be a vitamin D compound, preferably vitamin D | 10-28-2010 |
20100278914 | FRACTION OF MELISSA LEAF EXTRACT HAVING ANGIOGENESIS AND MMP INHIBITORY ACTIVITIES, AND COMPOSITION COMPRISING THE SAME - The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same. | 11-04-2010 |
20100285126 | PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The invention relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more pharmaceutically acceptable vehicles. The invention also relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more cyclodextrin derivatives. The invention also relates to processes for the preparation of such compositions. | 11-11-2010 |
20100303908 | PHARMACEUTICAL COMPOSITION COMPRISING DESLORATADINE - The present application relates to pharmaceutical compositions comprising desloratadine and a pharmaceutically acceptable polymer. | 12-02-2010 |
20100310654 | HOMEOPATHIC REMEDIES FOR USE BEFORE AND AFTER AESTHETIC INJECTABLE AND SURGICAL PROCEDURES TO MINIMIZE SWELLING AND BRUISING - The present invention generally relates to all-in-one homeopathic remedies for use before and after aesthetic injectable treatment and/or surgical procedures to help minimize swelling and bruising. | 12-09-2010 |
20100316713 | PHARMACEUTICAL COMPOSITION - The application relates to solid pharmaceutical compositions suitable for oral administration comprising an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions. | 12-16-2010 |
20100323012 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics - A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. | 12-23-2010 |
20100330180 | TABLETTING PROCESS - A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate. | 12-30-2010 |
20110002990 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF - The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 01-06-2011 |
20110002991 | PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID CONJUGATES AND PRODRUGS OF HYDROCODONE, METHOD OF MAKING AND USE THEREOF - The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 01-06-2011 |
20110002992 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF - The present invention relates to N-sulfonylated amino acid derivatives, where an aryl radical is linked via the sulfonyl group N-terminally to the amino acid and a radical which comprises at least one imino group and at least one further basic group which represents an optionally modified amino, amidino or guanidino group is linked C-terminally via the carbonyl group. The invention likewise relates to processes for preparing these compounds and to their use, in particular as inhibitors of matriptase. | 01-06-2011 |
20110008433 | Herbal Composition for Osteoarthritis - A novel herbal composition comprising of | 01-13-2011 |
20110008434 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL- ]AMINO]BENZONITRILE - The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation. | 01-13-2011 |
20110014285 | N-ACETYL CYSTEINE COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC EFFICACY OF ACETAMINOPHEN - The present invention relates to compositions for improving the efficacy of acetaminophen comprising a unit dose of acetaminophen and a therapeutic efficacy-enhancing amount of N-acetylcysteine, such that acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cysteine ranging from about 1:15 to about 1:0.000977, and use of such compositions for analgesic and antipyretic applications. | 01-20-2011 |
20110033538 | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation. | 02-10-2011 |
20110033539 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME - This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions. | 02-10-2011 |
20110038932 | Methods and materials for treating conditions associated with metabolic disorders - Disclosed are methods for treating a subject suffering from phenylketonuria and/or phenylalanemia. The methods include, in part, enterally administering to the subject a LNAA supplement in which the weight ratio of Leu to Val is greater than 2:1; in which the weight ratio of Leu to iLeu is greater than 3:1; or which includes one or more LNAAs and which further includes Lys. LNAA supplements are also disclosed. Also disclosed are methods for treating a subject suffering from a condition involving a metabolic disorder involving the metabolism of a first amino acid X. The method includes enterally administering to the subject a composition which (i) is substantially free from the first amino acid X and (ii) which includes a second amino acid Y that competes with amino acid X at a gastrointestinal tract transporter. | 02-17-2011 |
20110038933 | STABLE BENZIMIDAZOLE FORMULATION - A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents. | 02-17-2011 |
20110045069 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE - A description is given of precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease, in particular for the prevention or treatment of Type 2 diabetes. | 02-24-2011 |
20110045070 | COMBINATION THERAPY - The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time. | 02-24-2011 |
20110052690 | PROCESS FOR MANUFACTURE OF A MEDICAMENT WITH GRANULATION AND PAN COATING - A process for the manufacture of a coated tablet comprising a serotonin-norepinephrine reuptake inhibitor (SNRI), such as venlafaxine. According to one embodiment of the present invention, there is provided a process for manufacturing a coated tablet containing a serotonin-norepinephrine reuptake inhibitor, the process comprising preparing a granulate of the serotonin-norepinephrine reuptake inhibitor using a low shear granulator; compressing the granulation into a core; and applying a coating to the core using a pan coater. | 03-03-2011 |
20110070305 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MEBICAR - The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders. | 03-24-2011 |
20110076327 | Herbal Pain Killer Compositions - Disclosed are natural compositions including at least five core ingredients that provide pain relief without the side effects of synthetic pain relievers. Further provided are methods of making the disclosed herbal formulations or compositions, and methods of treating mammals that include administering the herbal compositions to a mammal in need thereof. | 03-31-2011 |
20110076328 | COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS - A composition for the treatment or prevention of a disorder resulting in hair loss comprises a cardiac glycoside as active principal. | 03-31-2011 |
20110086097 | Manufacture process for the preparation of an iron containing phosphate adsorbent - The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties. | 04-14-2011 |
20110104274 | NOVEL COMPOSITION AND USES THEREOF, IN PARTICULAR COSMETIC USES, FOR TREATING SKIN DEHYDRATION - The present invention relates to the use of a combination comprising gamma-linolenic acid and at least one green tea polyphenol, in which the ratio of the gamma-linolenic acid to the green tea polyphenol ranges from approximately 1 to approximately 10, for increasing the in vitro and ex vivo differentiation of keratinocytes. | 05-05-2011 |
20110104275 | METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS - The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders. | 05-05-2011 |
20110104276 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 05-05-2011 |
20110142934 | MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON - The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required. | 06-16-2011 |
20110150995 | Solid Dosage Forms of Essential Oils - Essential oils are extracted from plants and some have known medicinal properties. Some essential oils have been to known to show antibacterial, antifungal and antiviral activities. Some essential oils show sensual properties and others improve quality of sleep. The present invention describes a method to produce a solid dosage form (tablets or capsules) of these essential oils showing medicinal properties. The essential oils are adsorbed or absorbed on a substrate. The presence of a surfactant in the formulation helps solubilization of essential oils in the mouth cavity in vivo. Combination of various essential oils can be incorporated in the solid dosage forms. | 06-23-2011 |
20110150996 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE - The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation. | 06-23-2011 |
20110159096 | 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative For Pharmaceutical Use, and The Use Of a 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative With Substantially Undefined Crystal Shape For Preparing Said 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative - The present invention relates to voriconazole, processes of preparing voriconazole, and pharmaceutical compositions and therapeutic uses thereof. In particular, the present invention also relates to voriconazole prepared from voriconazole having a substantially undefined shape and/or crystal habit. The invention further relates to voriconazole having a modified sphericity factor and/or specific surface area and/or Sauter diameter compared to voriconazole known from the prior art. | 06-30-2011 |
20110165240 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a pharmaceutical oral fixed dose combination comprising
| 07-07-2011 |
20110182988 | GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM - This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract. | 07-28-2011 |
20110189282 | TABLET - The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet ( | 08-04-2011 |
20110212176 | CICLOPIROX AND CYTARABINE FOR THE TREATMENT OF LEUKEMIC DISORDERS - The present application relates to compositions and methods for treating leukemic disorders. In particular, the present application relates to compositions and methods for treating the leukemic disorders such as acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) using ciclopirox and cytarabine. | 09-01-2011 |
20110223250 | MULTI-VITAMIN AND MINERAL NUTRITIONAL SUPPLEMENTS - The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans. | 09-15-2011 |
20110223251 | BACTERIAL COMPOSITION - The present invention relates to a bacterial composition which has a long shelf-life, and a process for producing such compositions. The invention further relates to food products comprising the bacterial composition. | 09-15-2011 |
20110223252 | ELECTROLYTE PURGATIVE - The invention relates to compositions for use in purgatives, to purgatives comprising such compositions, and to methods for inducing purgation of the colon. The composition may comprise at least one water-soluble sodium salt; at least one water-soluble minimally degradable sugar in an amount, by weight, of from about 1 to about 3 times the weight of sodium ions in said composition; at least one water-soluble potassium salt in an amount, by weight, of from about 0.05 to about 1 time the weight of said sodium salt in said composition; and at least one water-soluble magnesium salt, wherein the weight of magnesium ions in said composition is from 0.1 to about 10 times the weight of sodium ions in said composition. | 09-15-2011 |
20110244040 | FILM-COATED SCORED TABLET - A film-coated scored tablet in which the forms of respective parts associated with a score line are optimized so as to more preferably divide the film along the score line is provided. | 10-06-2011 |
20110262540 | Solid Pharmaceutical Composition Comprising Exemestane - A solid pharmaceutical composition of exemestane, in particular for oral use and treatment of cancer, comprises micronized exemestane and anti-oxidant in a film-coated tablet. | 10-27-2011 |
20110268800 | Unsaturated fatty acids as thrombin inhibitors - A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the unsaturated fatty acid as a free fatty acid or a fatty acid radical of a triglyceride. The fatty acid has a chain length of 18 carbon atoms which are provided with 1 to 3 double bonds and the fatty acid has a chain length of 20 carbon atoms which are provided with 1 to 4 double bonds. The double bond or one of the double bonds are located in position 9 or 11 of the carbon chain. The unsaturated fatty acid is supplied in the all-cis configuration. The at least one unsaturated fatty acid prevents and/or treats or is used for producing a preparation for preventing and/or treating thrombosis and thromboembolic diseases. | 11-03-2011 |
20110268801 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 11-03-2011 |
20110293719 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 12-01-2011 |
20110305757 | NEW PHARMACEUTICAL COMBINATIONS - A pharmaceutical composition including a compound of Formula I (Compound I) or pharmaceutically acceptable salts thereof and one or more diuretics as effective components, wherein said one or more diuretics are selected from thiazide derivatives. Methods for preparing the pharmaceutical compound including Compound I and thiazide derivatives and its use for preventing or treating hypertension in mammals, particularly in humans. | 12-15-2011 |
20120015032 | COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs. | 01-19-2012 |
20120027856 | PHARMACEUTICAL PRODUCT COMPRISING YEAST - A pharmaceutical product containing an active pharmaceutical ingredient and having a controllable release of the active pharmaceutical ingredient. The pharmaceutical product comprises yeast that is capable of fermentation. The carbon dioxide production of the fermentation releases the active pharmaceutical ingredient from the pharmaceutical product. | 02-02-2012 |
20120045510 | TABLET SLEEVE FOR IMPROVED PERFORMANCE - A capsule-like dosage form, method for producing such dosage form and apparatus are disclosed. Such dosage form is achieved by applying a sleeve over the caplet to provide a coating which is smoother and easier to swallow than an uncoated caplet. The production of the capsule-like dosage form is readily facilitated by simple and inexpensive modifications to existing empty gelatin capsule making equipment. | 02-23-2012 |
20120058184 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES - The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis. | 03-08-2012 |
20120064160 | Fibrate-statin Combinations with Reduced Fed-fasted Effects - This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal. | 03-15-2012 |
20120082722 | METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS - Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists. | 04-05-2012 |
20120100213 | PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE - Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease. | 04-26-2012 |
20120121704 | Aliphatic Amine Polymer Salts for Tableting - The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions. | 05-17-2012 |
20120121705 | Pharmaceutical Or Cosmetic Or Dietetic Composition Suitable For Promoting A Hair Pigmentation Effect - The invention relates to the use of spermidine or a pharmaceutically acceptable derivative thereof as the active principle in a pharmaceutical, cosmetic or dietetic composition. The composition is used for promoting pigmentation of the hair, particularly the shaft of the hair. The invention also relates to the composition which promotes this pigmentation effect, the composition containing spermidine or a derivative thereof (such as a salt) as an active principle and is intended for topical or oral administration. | 05-17-2012 |
20120148673 | PEPTIDES THAT DOWN REGULATE THE ACTIVITY OF PLASMA MEMBRANE TRANSPORTERS INCLUDING SODIUM-D-GLUCOSE COTRANSPORTER SGLT1 - The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof. Furthermore, the present invention relates to a method for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, said method comprising administering to a patient in need of such amelioration, prevention and/or treatment a pharmaceutically active amount of said regulatory protein RS1 fragment as defined herein or a nucleic acid molecule encoding said regulatory protein RS1 fragment. Moreover, the present invention relates to the use of said regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of food, feed and/or food supplements. | 06-14-2012 |
20120156295 | ANTIBIOTIC COMPOUNDS - Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to | 06-21-2012 |
20120164222 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 06-28-2012 |
20120171288 | SOLID PHARMACEUTICAL FIXED DOSE COMPOSITIONS COMPRISING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The present invention is directed to solid stable pharmaceutical fixed dose compositions comprising irbesartan, amlodipine besilate and pharmaceutically acceptable excipients, to their preparation and to their therapeutic application. | 07-05-2012 |
20120177737 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 07-12-2012 |
20120183613 | Novel Pharmaceutical Composition - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 07-19-2012 |
20120207832 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 08-16-2012 |
20120225123 | Use of Synergistic Combinations of an Avermectin and an Antineoplastic Compounds for the Treatment of Hematological Malignancies - The disclosure relates to a method of treating a hematological malignancy comprising administering to a subject in need thereof a synergistic combination of a first compound comprising an effective amount of one or more Avermectins and a second compound comprising a chemotherapeutic, preferably daunorubicin, cyarabine, doxorubicin, idarubicin mitoxantrone, amsacrine, and mixtures thereof. | 09-06-2012 |
20120231078 | METHOD TO REDUCE THE SYMPTOMS OF HEARTBURN AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) BY SPECIFIC POLYSACCHARIDES - The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms of heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low pH. Such a preparation is particularly effective in reducing the symptoms of heartburn and/or gastro-oesophageal reflux disease, particularly when consumed in dry form. | 09-13-2012 |
20120237601 | Pharmaceutical Compositions Comprising Mycophenolic Acid or Mycophenolate Salt - The invention provides a solid dosage form, e.g. a tablet, comprising mycophenolic acid or mycophenolate salt and a process for its production. | 09-20-2012 |
20120244219 | STABLE BENZIMIDAZOLE FORMULATION - A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. | 09-27-2012 |
20120263790 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 10-18-2012 |
20120263791 | FOMULATION COMPRISING 1 H-QUINAZOLINE-2, 4-DIONE AMPA RECEPTOR ANTAGONISTS, IN THE FORM OF IMMEDIATE RELEASE TABLETS AND PREPARATION THEREOF - The present invention relates to pharmaceutical formulations comprising a 1H-quinazoline-2,4-dione AMPA receptor antagonist. More particularly, the invention relates to immediate release formulations comprising such a compound. | 10-18-2012 |
20120294942 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST - The invention relates to novel processes for the preparation of high-purity roflumilast. | 11-22-2012 |
20130039983 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS - The invention relates to a new process for the production and/or purification of the salt of the compound (S)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide, i.e. ralfinamide, or the respective R-enantiomer, with methanesulfonic acid in high yields and very high enantiomeric and chemical purity in the form of the crystalline anhydrous polymorph identified as form A, wherein said salt is substantially free from impurities having genotoxic effect, such as (C | 02-14-2013 |
20130039984 | Manufacture process for the preparation of an iron containing phosphate adsorbent - The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties. | 02-14-2013 |
20130064892 | CELLULOSIC GEL MATERIAL AS A PHARMACEUTICAL EXCIPIENT - A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described. | 03-14-2013 |
20130064893 | STABILIZED PHARMACEUTICAL COMPOSITION - The invention relates to stabilized pharmaceutical composition comprising pregabalin and a disaccharide or higher polyol as stabilizer and optionally a conventional pharmaceutically acceptable carrier. The stabilized pharmaceutical composition according to the invention is useful in the treatment of a number of diseases such as epilepsy, Alzheimer's disease or Parkinson's disease. | 03-14-2013 |
20130078306 | MEDICAMENTS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method | 03-28-2013 |
20130084334 | PHARMACEUTICAL COMPOSITIONS HIGHLY DOSED WITH BIOTIN - The invention relates to novel pharmaceutical compositions highly dosed with biotin, as well as to the use thereof in treating visual impairments which are related, in particular, to optic atrophy. | 04-04-2013 |
20130084335 | IVABRADINE-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing ivabradine or a pharmaceutically acceptable salt thereof. The invention further relates to a method for the preparation of such a composition. | 04-04-2013 |
20130095182 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders - The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence. | 04-18-2013 |
20130108699 | HIGHLY DISPERSIBLE GRANULATE FOR THE PREPARATION OF FORMULATIONS OF HIGH DOSAGE ACTIVE SUBSTANCES AND PROCEDURE FOR OBTAINING HIGH DOSAGE ACTIVE SUBSTANCES THEREOF | 05-02-2013 |
20130115290 | COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX - Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. | 05-09-2013 |
20130122091 | POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS AND THEIR METHODS OF USE - Compositions including synergistic combinations of polydeoxyribonucleotides and methyl amides, such as carnitine, are provided. Such compositions may include further optional active ingredients, such as a calcium salt, vitamins of the D or B groups, a sodium salt and a potassium salt, preferably used in combination. | 05-16-2013 |
20130136794 | HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF - Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. | 05-30-2013 |
20130149380 | USE OF DIATOMACEOUS EARTH IN THE PHARMACEUTICAL INDUSTRY - The present invention is related to solid pharmaceutical preparations containing diatomaceous earth (diatomite) or a natural mineral mixture containing diatomaceous earth as filler besides the active ingredient and optional other auxiliary agents. A further object of the invention is a method for manufacturing such pharmaceutical preparations. | 06-13-2013 |
20130156855 | ACNE TREATMENT - One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine. | 06-20-2013 |
20130164378 | Special Prenatal Nutritional Supplement and Design Method Thereof - A special prenatal nutritional supplement, characterized as containing active ingredients such as nutrients (including at least one or more vitamins), minerals, or a mixture of pharmaceutical and standard food material. The design method of this special prenatal nutritional supplement is that the type and dosage of the ingredients are defined each day in accordance with the chronological order of the development of the fetus. The product is arranged or displayed like a calendar in a day by day order. | 06-27-2013 |
20130171255 | LAXATIVE - The invention relates to a laxative with improved compliance, containing polyethylene glycol (PEG). A medicinal product according to the invention is suitable for treating chronic obstipations and is characterized in that it comprises two components, A and B, which are spatially separated from one another, component A comprising a polyethylene glycol (PEG) and component B comprising at least one electrolyte. | 07-04-2013 |
20130177646 | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance - Solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptically disturbing sensations, and where the at least one film coating is devoid of nicotine and devoid of buffer. | 07-11-2013 |
20130177647 | METHODS FOR MANIPULATING SATIETY - Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal. | 07-11-2013 |
20130183384 | IMMEDIATE RELEASE MULTI UNIT PELLET SYSTEM - The present invention relates to a multiple unit pellet system (MUPS) in form of a tablet containing a pharmaceutically active ingredient, characterized in that the MUPS is an optionally coated immediate release pharmaceutical dosage form for oral administration. | 07-18-2013 |
20130189362 | NOVEL DOSAGE FORMULATION - The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I | 07-25-2013 |
20130189363 | BETA-HAIRPIN PEPTIDOMIMETICS - β-Hairpin peptidomimetics of the general formula Cyclo (-Xaa | 07-25-2013 |
20130195978 | Darunavir Compositions - The present invention relates to an oral pharmaceutical composition of amorphous darunavir. | 08-01-2013 |
20130202701 | (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[- 3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome - The invention relates to a pharmaceutical dosage form comprising (1r,4r)-6′-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro-[cyclohexane-1,1′-pyrano[3,4,b]-indol]-4-amine or a physiologically acceptable salt thereof, for use in the treatment of fibromyalgia or chronic fatigue syndrome. | 08-08-2013 |
20130202702 | ORAL FORMULATIONS - A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed. | 08-08-2013 |
20130224298 | Two-Phase Preparation And Use Thereof For The Treatment Of Herpes - The invention relates to a novel two-phase preparation for use as a food supplement, dietary substance, and/or medicament. The medical use thereof for helping the immune system fight against viral diseases, especially herpes, is particularly preferred. Said preparation may have two different phases which may be used in a chronologically staggered manner, mutually blocking agents being in different phases and mutually boosting agents being in the same phase. | 08-29-2013 |
20130224299 | Novel Process For The Preparation Of Roflumilast - A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight. | 08-29-2013 |
20130230591 | PEPTIDE FOR USE AS A MEDICAMENT, IN PARTICULAR FOR THE TREATMENT OF CANCER - The invention relates to a peptide having the sequence SEQ.1: INWLKIAKKVAGML-NH2 and one or more of the variants thereof selected from among the sequences SEQ.2 to SEQ.25, or one of the mixtures thereof. The peptides are used especially as a medicament, in particular for the treatment of cancer. The invention also relates to a pharmaceutical composition including the peptides. | 09-05-2013 |
20130243860 | STANDARDIZED PLANT EXTRACT, PROCESS FOR OBTAINING THE SAME AND USES THEREOF - The present invention refers to a process for obtaining a standardized extract having antinociceptive, anti-inflammatory and antipyretic properties, from at least one part of a plant of genus | 09-19-2013 |
20130251803 | ONCE DAILY FORMULATION OF LACOSAMIDE - A modified release formulation of lacosamide suitable for once-daily administration. | 09-26-2013 |
20130273160 | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES - The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations. | 10-17-2013 |
20130273161 | IMMUNOSUPPRESSANT FORMULATIONS - The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound. | 10-17-2013 |
20130280328 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH 6-MERCAPTOPURINE - Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects. | 10-24-2013 |
20130295178 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES - The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis. | 11-07-2013 |
20130309301 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 11-21-2013 |
20130337062 | GASTRO-RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS - The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes. | 12-19-2013 |
20130337063 | PHARMACEUTICAL COMPOSITIONS OF MARAVIROC AND PROCESS FOR THE PREPARATION THEREOF - The present disclosure relates to solid dosage forms comprising the CCR5 co-receptor antagonist maraviroc. More particularly, the present disclosure relates to a solid oral dosage form containing maraviroc which has favorable disintegration properties. | 12-19-2013 |
20130344148 | Oral Composition - The present invention relates to a tablet composition comprising a particle and a pharmaceutically acceptable carrier, wherein the particle comprises an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular solid dispersion of a drug in a polymeric matrix and the submicron domain is a submicron drug particle. The tablet may further comprise a micronized drug particle. The pharmaceutically acceptable carrier comprises a binder, a filler, a lubricant, and optionally a gelling agent, a glidant and an anti-sticking agent. | 12-26-2013 |
20130344149 | Oral Dosage Forms for Modified Release Comprising Tasocitinib - The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms. | 12-26-2013 |
20140010877 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts. | 01-09-2014 |
20140017311 | DRIED PRODUCT AND A PROCESS FOR MANUFACTURING THE PRODUCT - A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance. | 01-16-2014 |
20140030331 | METHOD OF TREATING MULTIPLE SCLEROSIS - The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequalae after multiple sclerosis attacks by administering biotin. | 01-30-2014 |
20140030332 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 01-30-2014 |
20140030333 | Novel Pharmaceutical Preparation for Preeclampsia, Eclampsia, and Toxemia and Their Related Symptoms and Related Disorders of Pregnancy - A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | 01-30-2014 |
20140037730 | COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX - Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. | 02-06-2014 |
20140044784 | COMBINED FORMULATION WITH IMPROVED STABILITY - Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability. | 02-13-2014 |
20140050786 | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITISERS - The present invention relates to combinations of triazine derivatives and of insulin sensitisers. | 02-20-2014 |
20140065214 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE - The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 03-06-2014 |
20140065215 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF NITAZOXANIDE - Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided. | 03-06-2014 |
20140065216 | Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder - A bioactive dose for delivering a bioactive agent to a mammal, includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit, the rapid release coating containing a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards an ideal absorptive pH or towards an ideal pH to hinder absorption of the at least one bioactive agent given the pKa that least at one bioactive agent. A modified liquid that is administered prior to, contemporaneous with, or following the delivery of a bioactive agent is also described. The liquid includes a pH modifier selected to control the pH of the liquid to a predetermined range so that the modified liquid rapidly modulates the pH of bodily fluids to enhance or hinder absorption of the bioactive agent. | 03-06-2014 |
20140065217 | MULTILAYER TABLET - A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques. | 03-06-2014 |
20140065218 | NOVEL LACTIC ACID BACTERIA AND COMPOSITIONS CONTAINING THEM AGAINST BACTERIAL COLDS - The invention describes a microorganism of the order of lactic acid bacteria or an analogue, fragment, derivative, mutant or combination thereof, wherein the microorganism, or analogue, fragment, derivative, mutant or combination thereof can coaggregate with | 03-06-2014 |
20140093565 | A PHARMACEUTICAL COMPOSITION COMPRISING A HDAC INHIBITOR AND A STEROID AND THE USE THEREOF - The invention relates to a pharmaceutical composition comprising a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments. | 04-03-2014 |
20140093566 | PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE - Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease. | 04-03-2014 |
20140093567 | Method for Producing Orodispersible Tablets - A method for easily producing orodispersible tablets that secure an eluting behavior of a principal agent in the digestive tract and mask unpleasant taste in the oral cavity is provided. Provided is a method for producing orodispersible tablets which includes mixing an additive to a principal agent to form principal agent particles as a granulation process, coating the principal agent particles with a coating agent to form coated particles as a coating process, and tableting the coated particles to form tablets as a tableting process, wherein the additive used in the granulation process contains a pH regulator, and the coating agent used in the coating process contains a pH-dependent polymer dissolving at pH 5 or more. | 04-03-2014 |
20140099367 | USE OF SPIRONOLACTONE-BASED COMPOSITION THAT EXHIBITS AN INHIBITORY ACTION ON T-LYMPHOCYTE ACTIVATION WHICH IS USEFUL FOR PREVENTING AND/OR TREATING MULTIPLE SCLEROSIS - The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies. | 04-10-2014 |
20140127297 | NUTRACEUTICAL COMPOSITION FOR LIMITING THE ABSORPTION OF DIETARY LIPIDS AND FOR INDUCING WEIGHT LOSS, COMPRISING, AS ACTIVE AGENT, AT LEAST ONE EXTRACT OF CARROT - The invention relates to a nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss in a human or animal mammal, characterized in that it comprises as active agent at least one extract of carrot, at least half of which is fibres. | 05-08-2014 |
20140127298 | MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON - The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required. | 05-08-2014 |
20140141081 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 05-22-2014 |
20140141082 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses - The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed. | 05-22-2014 |
20140154317 | Pharmaceutical Composition for Treatment of Helicobacter Pylori Associated Diseases - An oral pharmaceutical composition for the treatment of | 06-05-2014 |
20140170218 | COMPOSITIONS CONTAINING BROCCOLI SEEDS FOR TREATMENT OR PREVENTING PROSTATE CANCER - The invention relates to a composition for treating or preventing prostate cancer or the recurrence thereof; including a non-aqueous extract of non-germinated broccoli seeds of the | 06-19-2014 |
20140178472 | Methods of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 06-26-2014 |
20140199393 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-17-2014 |
20140212491 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 07-31-2014 |
20140220129 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester - Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters. | 08-07-2014 |
20140234417 | TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF - This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]- | 08-21-2014 |
20140248348 | USE OF SALMONELLA FLAGELLIN DERIVATIVE IN PREPARATION OF DRUG FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASES - The application of flagellin derivative CZLC31 from | 09-04-2014 |
20140248349 | PROCESS FOR THE PREPARATION OF A SOLID, ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION - The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases. | 09-04-2014 |
20140271855 | SOVAPREVIR TABLETS - The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein. | 09-18-2014 |
20140271856 | ORALLY DISINTEGRABLE TABLETS - An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration. | 09-18-2014 |
20140294957 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS - The invention relates to niclosamide and derivates thereof, which effectively inhibit transcription of the S100A4 gene, resulting in inhibition and/or reduction of S100A4-induced cell motility, invasiveness, metastasis and proliferation of human cancer cells. | 10-02-2014 |
20140302142 | COMPOSITIONS AND METHDS FOR ENHANCING PENETRATION OF BIOLOGICALLY ACTIVE SUBSTANCES INTO TISSUES OR ORGANS - According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate. | 10-09-2014 |
20140335179 | MICRONIZED CRYSTALS OF ATORVASTATIN HEMICALCIUM - The present invention relates to micronized crystals of atorvastatin hemi-calcium, a method for the preparation of micronized crystals of atorvastatin hemi-calcium and a pharmaceutical dosage form comprising said micronized crystals of atorvastatin hemi-calcium. | 11-13-2014 |
20140348917 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE - The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form. | 11-27-2014 |
20140348918 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA - The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 11-27-2014 |
20140348919 | ANTIBIOTIC COMPOUNDS - This invention relates to novel purified compounds of Formula I. The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula I and pharmaceutically acceptable salts and derivatives. The present invention further relates to processes for the production of the novel antibacterial compounds by fermentation of the microorganism belonging to | 11-27-2014 |
20140348920 | Method of Treating Multiple Sclerosis - The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin. | 11-27-2014 |
20140356429 | TABLET CONTAINING FERRIC CITRATE - The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer | 12-04-2014 |
20140356430 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-- 3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE - Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition. | 12-04-2014 |
20140356431 | ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION - The present invention provides an FTD and TPI-containing orally administrable pharmaceutical composition which can be orally administered and is stable even under high-humidity conditions. | 12-04-2014 |
20140370087 | NOVEL USE OF ANGIOGENIN - The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma. | 12-18-2014 |
20140370088 | COMPOSITIONS AND METHODS FOR DELIVERY OF OMEPRAZOLE PLUS ACETYLSALICYLIC ACID - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof. | 12-18-2014 |
20140370089 | DIETHYL-[6-(4-HYDROXYCARBAMOYL-PHENYL-CARBAMOYLOXY-METHYL)-NAPHTHALEN-2-YL- -METHYL]-AMMONIUM CHLORIDE FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY - The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. | 12-18-2014 |
20150017243 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION - Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or | 01-15-2015 |
20150037414 | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin - A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (T | 02-05-2015 |
20150037415 | PROCESS FOR THE PREPARATION OF A SOLID, ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION - The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases. | 02-05-2015 |
20150050338 | METHOD FOR TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME - The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | 02-19-2015 |
20150050339 | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Method of Making and Use Thereof - The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 02-19-2015 |
20150056280 | ISOTOPOLOGUES OF 5-AZACYTIDINE - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. | 02-26-2015 |
20150079170 | NOVEL TABLET DOSAGE FORM - The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients. | 03-19-2015 |
20150093438 | Tramadol for Treating Depression - There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub-analgesic amount is from about 60 to 80 mg, of tramadol or a salt thereof. | 04-02-2015 |
20150098995 | Tabletting Process - A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Particular anti-static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate. | 04-09-2015 |
20150098996 | NICOTINE LOZENGE - A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder. | 04-09-2015 |
20150110872 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The invention also relates to the combination of sulforaphane or a derivative thereof and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present invention also relates to the combination of a broccoli extract or powder and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present provides compositions and methods relating to these combinations. | 04-23-2015 |
20150118304 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MAGNESIUM - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations. | 04-30-2015 |
20150125526 | Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases - The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. | 05-07-2015 |
20150132381 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES - The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis. | 05-14-2015 |
20150147393 | PALATABLE ORAL VETERINARY COMPOSITIONS - The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions. | 05-28-2015 |
20150147394 | PHARMACEUTICAL COMPOSITION CONTAINING FIMASARTNA AND HYDROCHLOROTHIAZIDE - The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof. | 05-28-2015 |
20150290218 | CO-MICRONISATION PRODUCT COMPRISING ULIPRISTAL ACETATE - The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof. | 10-15-2015 |
20150299199 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 10-22-2015 |
20150306126 | SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM - This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. | 10-29-2015 |
20150328191 | USE OF PIDOTIMOD TO TREAT PSORIASIS - The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat psoriasis. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either systemically or topically. | 11-19-2015 |
20150342852 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN, HAIR AND/OR MUCOUS MEMBRANES AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Compounds of general formula (I): R | 12-03-2015 |
20150352048 | VALSARTAN-AMLODIPINE COMPOUND SOLID PREPARATION AND PREPARATION METHOD THEREFOR - The present invention relates to a compound solid preparation and the preparation method therefor and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared by preparing wet valsartan particles from a mixture obtained by mixing valsartan and a pharmaceutic adjuvant with an ethanol aqueous solution as a wetting agent and drying the wet valsartan particles. The amlodipine premix is prepared by mixing amlodipine and a pharmaceutic adjuvant. The valsartan-amlodipine compound solid preparation according to the present invention and the preparation method thereof can prevent the two main ingredients, amlodipine and valsartan, from interfering each other, and the preparation method is relatively simple and suitable for large-scale industrial production. | 12-10-2015 |
20160000732 | ORAL PHARMACEUTICAL COMPOSITIONS OF OSPEMIFENE - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof having an average particle size of more than 20 microns and one or more pharmaceutically acceptable excipients comprising at least one solubility enhancing agent. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 01-07-2016 |
20160000857 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinenmia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 01-07-2016 |
20160022679 | PHARMACEUTICAL COMBINATION DRUG - The present invention relates to a pharmaceutical combination preparation comprising fimasartan and rosuvastatin as active ingredients together with meglumine. | 01-28-2016 |
20160030374 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA - According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris. | 02-04-2016 |
20160038468 | RIFAXIMIN FOR USE IN THE TREATING OF VAGINAL INFECTIONS - This disclosure relates to rifaximin—for use in the treatment of bacterial vaginal infections. The disclosure also relates to the use of rifaximin for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronidazole resistant. The disclosure also relates to the use of rifaximin to treat patients with vaginal infections who have relapsed following prior treatment or who have bacteria resistant to antibiotics other than rifaximin. | 02-11-2016 |
20160045479 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance. | 02-18-2016 |
20160052931 | DEUTERATED MORPHINE DERIVATIVES - The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine derivatives show high and selective μ-opioid receptor binding activity leading to the benefit of higher analgesic activity at lower dosages inducing thereby reduced adverse effects compared to the hydrogenated derivatives. The compounds of the invention are useful for example in the treatment of pain or can be used as antitussive agents with a reduced risk of the possibility of drug abuse. | 02-25-2016 |
20160058739 | USE OF PIDOTIMOD TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat inflammatory bowel disease. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally. | 03-03-2016 |
20160058823 | COMPOSITION AND USE OF A DIETARY SUPPLEMENT - Composition of a dietary supplement, characterised in that it comprises a mixture of at least a-casein tryptic hydrolysate, Siberian or Asian Ginseng root powder, and lyophilised melon extract. | 03-03-2016 |
20160068463 | PRODUCTION OF SALTS OF 4-HYDROXYBUTYRATE USING BIOBASED RAW MATERIALS - Gamma-butyrolactone (“GBL”) and Gamma-hydroxybutyrate (“GHB”) having a unique carbon footprint as defined by the percent modern carbon (pmc) are described herein. The percent modern carbon can be controlled by varying the amounts of biobased, renewable starting materials and petroleum-based starting materials to prepare GBL or GHB having a defined pmc or by preparing mixtures of GBL or GHB prepared from biobased renewable starting materials and GBL or GHB prepared from petroleum-based starting materials. | 03-10-2016 |
20160081971 | METHOD FOR PRODUCING DOSAGE FORM COMPRISING ODANACATIB - The present invention relates to a method for producing a dosage form, preferably a dosage form for immediate release, containing odanacatib wherein the method comprises the granulation with a specific granulation fluid. The invention further relates to a dosage form obtained according to said method. | 03-24-2016 |
20160106766 | SOLID COMPOSITION FOR ORAL ADMINISTRATION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND VITAMIN D - An improved solid pharmaceutical composition for oral administration comprising ibandronic acid or a pharmaceutically acceptable salt thereof, vitamin D and medium chain triglycerides or totally or partially hydrogenated oils which confer desirable physico-chemical properties to a solid formulation for oral administration suitable for the treatment of bone diseases and disorders of calcium metabolism. | 04-21-2016 |
20160120802 | ORALLY-DISINTEGRATING OSELTAMIVIR TABLET AND METHOD FOR PREPARING THE SAME - An orally-disintegrating oseltamivir tablet, including: between 10 and 50 wt. % of a taste-masking pellet, between 30 and 80 wt. % of a first filler, between 1 and 6 wt. % of a first adhesive, between 2 and 10 wt. % of a disintegrant, between 0 and 5 wt. % of a flavoring agent, between 0.5 and 2.5 wt. % of a lubricant. The taste-masking pellet includes: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt of oseltamivir and accounts for between 10 and 40 wt. % of a total weight of the taste-masking pellet. The coating layer include a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the taste-masking pellet. The diameter of the taste-masking pellet is between 0.10 and 0.50 mm. | 05-05-2016 |
20160120812 | Methods of Preparing Tamper Resistant Solid Oral Dosage Forms - Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. | 05-05-2016 |
20160120892 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 05-05-2016 |
20160120925 | DRUG CONTAINING THYME AND PRIMROSE OR THYME AND IVY AS A PDE-4 INHIBITOR - The invention relates to an extract from thyme ( | 05-05-2016 |
20160129062 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION - A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and | 05-12-2016 |
20160143909 | PHARMACEUTICAL COMPOSITION - Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity. | 05-26-2016 |
20160151395 | Tabletting Process | 06-02-2016 |
20160158157 | ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION - The present invention relates to an oral pharmaceutical fixed dose composition for use in the treatment of | 06-09-2016 |
20160158202 | Low Dose Pharmaceutical Composition - This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity. This invention also provides a process for preparing the low dose pharmaceutical composition, the process comprising: dissolving or adsorbing or blending deferasirox and at least one excipient to produce a dispersion of deferasirox; and processing the dispersion to produce a desired dosage form. | 06-09-2016 |
20160166659 | DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATION | 06-16-2016 |
20160193196 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | 07-07-2016 |
20160199305 | PHARMACEUTICAL DOSAGE FORM | 07-14-2016 |
20160199396 | UNIT DOSAGE FORM COMPRISING EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITHIC TABLET COMPRISING DARUNAVIR AND RITONAVIR | 07-14-2016 |
20160250185 | PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPIL | 09-01-2016 |
20160374947 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR - The present invention relates to a pharmaceutical composition comprising
| 12-29-2016 |